Pasithea Therapeutics Corp

KTTA | $7.15 -1.19% 540

(0.0% 1d) (-0.9% 1m) (1557.3% 1y) (0.0% 2d) (-0.6% 3d) (-0.6% 7d) (55.01% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,453,267
https://pasitheaclinics.com
Sec Filling | Patents | 2 employees

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability. The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services to patients who personally pay for those services. Pasithea has partnered with two successful clinics for immediate exposure in locations across Los Angeles, New York City and London.

treatment

add to watch list Paper trade email alert is off

Press-releases

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 20.1% | O: 4.39% H: 4.37% C: 4.37%
pas-004 trial therapeutics

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 1.57% | O: 0.0% H: 11.29% C: 5.03%
pas-004 therapeutics

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Published: 2024-01-02 (Crawled : 14:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| -3.92% | O: 0.0% H: 14.86% C: 8.78%
pas-004 fda cancer application therapeutics advanced

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Published: 2023-12-28 (Crawled : 22:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| -8.85% | O: -1.64% H: 9.49% C: -3.55%
meeting therapeutics

Pasithea Therapeutics Announces Results from 2023 Annual Meeting
Published: 2023-12-19 (Crawled : 22:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 9.69% | O: -16.72% H: 12.97% C: 3.74%
meeting therapeutics results

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
Published: 2023-12-11 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 18.46% | O: 176.71% H: 4.77% C: -46.72%
pas-004 positive cancer preclinical therapeutics

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Published: 2023-11-29 (Crawled : 03:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 0.42% | O: -2.99% H: 0.17% C: -5.07%
meeting therapeutics

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| 7.08% | O: 2.41% H: 14.71% C: 4.12%
pas-004 fda meeting therapeutics

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540

| -5.15% | O: -3.9% H: 4.05% C: 4.05%
pas-003 antibody als treatment therapeutics

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
Published: 2023-09-14 (Crawled : 12:30) - globenewswire.com
KTTA | $7.15 -1.19% 540